{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~52 mi. (Paso de las Limas, Mexico, +192 more cities)
facility
COI Centro Oncológico Intl. S.A.P.I. de C.V._ S.F.
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
city
~54 mi. (Toluca de Guadalupe, Mexico, +126 more cities)
facility
Phylasis Clinicas Research S. de R.L. de C.V.
drug
nivolumab, +2 more drugs
drug type
chemotherapy, +1 more type
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~95 mi. (Orizaba, Mexico, +383 more cities)
facility
Clinica Medica Research SC
biomarker
ER Negative, +2 more biomarkers
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~95 mi. (Orizaba, Mexico, +158 more cities)
facility
CLIMERS Clinical Medical Research ( Site 0506)
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types